佐力药业(300181) - 2026年1月15日投资者关系活动记录

Group 1: OTC Development - In 2025, the company experienced good growth in the OTC sector, attributed to the optimization of the sales organization and strategic partnerships with chain pharmacies [1] - The company plans to enhance the "hospital + community" dual-drive strategy in 2026, focusing on increasing coverage in national chain pharmacies and promoting end-user sales through education [1] - The goal is to increase the C-end sales proportion to 20%-30% [2] Group 2: Product Performance - The Bai Ling series saw a year-on-year growth of approximately 30% in the first three quarters of 2025 [2] - The company expects to maintain steady growth and expand market share through price-volume strategies following the nationwide procurement implementation [2] Group 3: Acquisition and Financial Management - Payment for the acquisition of the Future Pharmaceutical asset group will be phased based on the completion of various milestones outlined in the acquisition agreement [2] - Sales expenses in 2026 will fluctuate based on marketing strategies and product structure changes, with a focus on cost control and efficiency improvements [2]